Global Duchenne Muscular Dystrophy Drugs Market Overview: Trends Shaping Growth to 2029

November 12, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Duchenne Muscular Dystrophy Drugs Industry In 2025?

The duchenne muscular dystrophy drugs market has seen rapid expansion in recent years. It is anticipated to grow from $2.83 billion in 2024 to $3.2 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.2%. The growth observed in the past period is attributable to improvements in diagnostic capabilities, an increase in patient registries and data collection, rising demand, a developing pipeline of clinical-stage therapies, and an uptick in regulatory incentives.

The duchenne muscular dystrophy drugs market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $5.31 billion by 2029, driven by a compound annual growth rate (CAGR) of 13.4%. This anticipated growth during the forecast period is fueled by several factors, including an increase in early-stage biotech companies entering the market, the expansion of real-world evidence and post-marketing data, escalating health expenditure, a heightened demand for early intervention therapies, and an uptick in the off-label application of corticosteroids. Key trends anticipated during this period encompass a surge in biotech innovation, the incorporation of digital health solutions and wearable technology, a rising focus on personalized and mutation-specific treatments, and significant progress in gene therapy and CRISPR technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24213&type=smp

What Are The Main Drivers Boosting The Duchenne Muscular Dystrophy Drugs Industry’s Expansion?

The expanding field of personalized medicine is projected to fuel the expansion of the Duchenne muscular dystrophy (DMD) drugs market in the future. This medical strategy involves customizing treatments for each patient, considering their unique genetic makeup, environmental influences, and lifestyle choices, thereby enhancing therapeutic results and overall patient management. Demand for personalized medicine is on the rise, driven by breakthroughs in genomic technologies that allow for accurate detection of genetic differences and the development of customized therapies for individuals. For Duchenne muscular dystrophy (DMD) drugs, personalized medicine is beneficial as it provides specific therapies designed according to each patient’s genetic profile, leading to more efficacious treatments. Furthermore, it improves drug development processes by concentrating on particular genetic mutations, which in turn enhances treatment efficacy and patient care generally. As an illustration, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, revealed that the U.S. Food and Drug Administration (FDA) sanctioned 26 new personalized medicines in 2023. This marks a considerable jump from the 12 approved in 2022. Consequently, the expansion of personalized medicine acts as a key driver for the Duchenne muscular dystrophy (DMD) drugs market.

What Are The Major Segment Types Covered In The Duchenne Muscular Dystrophy Drugs Market?

The duchenne muscular dystrophy drugs market covered in this report is segmented –

1) By Drug Type: Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) Exon Skipping Drugs: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Other Exon Skipping Therapies

2) Corticosteroids: Prednisone, Deflazacort, Other Corticosteroids

3) Gene Therapy: Micro-dystrophin Gene Therapy, CRISPR/Cas9-Based Gene Editing, Stem Cell-Based Gene Therapy, Other Gene Therapies

4) Other Drug Types: Utrophin Modulators, Anti-Inflammatory Agents, Antisense Oligonucleotides, Myostatin Inhibitors, Other Supportive Therapies

Which Ongoing Trends Are Expected To Shape The Duchenne Muscular Dystrophy Drugs Market Outlook?

Key companies within the Duchenne muscular dystrophy (DMD) drugs market are prioritizing the creation of advanced solutions, including corticosteroids, to enhance muscle strength, slow the disease’s progression, and improve overall patient results. Corticosteroids are a type of steroid hormone, either naturally occurring in the adrenal glands or synthetically manufactured as drugs, that work by reducing inflammation and suppressing the immune system. For example, in March 2024, Catalyst Pharmaceuticals, a US-based biopharmaceutical company, introduced AGAMREE (vamorolone) oral suspension 40 mg/mL, which is a Food and Drug Administration (FDA)-approved treatment for Duchenne muscular dystrophy in patients aged two and older. AGAMREE functions as a corticosteroid by decreasing inflammation and stabilizing muscle cell membranes, thereby assisting in the deceleration of disease progression.

Who Are The Key Multinational Companies Dominating The Duchenne Muscular Dystrophy Drugs Market?

Major companies operating in the duchenne muscular dystrophy drugs market are Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb, Novartis AG, GSK plc, Eli Lilly and Company, Aurobindo Pharma Limited, Italfarmaco S.p.A, Sarepta Therapeutics Inc., PTC Therapeutics Inc., FibroGen Inc., Wave Life Sciences Ltd., Solid Biosciences Inc., NS Pharma, Capricor Therapeutics Inc., Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc., EspeRare Foundation, Satellos Bioscience Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-drugs-global-market-report

What Are The Key Regional Factors Influencing The Duchenne Muscular Dystrophy Drugs Market Growth?

North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the duchenne muscular dystrophy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Duchenne Muscular Dystrophy Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24213&type=smp

Browse Through More Reports Similar to the Global Duchenne Muscular Dystrophy Drugs Market 2025, By The Business Research Company

Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Nucleic Acid Based Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795